Výsledky vyhledávání - "J. M. Trigo Perez"

764 Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC)

Autor: M. J.Méndez Vidal, Avivit Peer, Luke T. Nordquist, Oliver Sartor, Roujia Li, Paul Schwarzenberger, J. M. Trigo Perez, Stefano Severi, Giuseppe Procopio, Schwarzenberger Paul, Neil Mariados, C. Thellenberg Karlsson, Kalevi Pulkkanen, Daniel Keizman, Stephen Frank

Publikováno v: European Urology Supplements. 15:e764-e764a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::097d8414af0fc9f0ce4af40e8b69aa58
https://doi.org/10.1016/s1569-9056(16)60766-2

Zobrazit plný text záznamu

AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data

Autor: Joachim G.J.V. Aerts, Arnaud Scherpereel, M-J. Ahn, Jonah Kim, Antonio Chella, B. Lutiger, J. M. Trigo Perez, Anders Vikström, Radj Gervais, Achim Rittmeyer, Fabrice Barlesi, Vera Gorbunova, N. Ferrer

Publikováno v: Journal of Clinical Oncology. 29:7562-7562

7562 Background: 1L bev-based therapy followed by mtc bev offers clinical benefit over standard chemotherapy alone, as do either 1L cis-pem or mtc pem. AVAPERL1 is designed to investigate if contin...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a598f5f2c091c4667b1ed3cc45b59df3
https://doi.org/10.1200/jco.2011.29.15_suppl.7562

Zobrazit plný text záznamu

Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients

Autor: Bella Pajares, C. Quero Blanco, A. Rueda, Begoña Jimenez, E. Alba, M. I. Saez Medina, J. M. Trigo Perez

Publikováno v: Journal of Clinical Oncology. 29:5594-5594

5594 Background: The addition of cetuximab to weekly paclitaxel have shown high efficacy in the first-line treatment of patients with recurrent /metastatic squamous cell carcinoma of the head and n...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4101fc3eaeb52b9270776c2efd6a25ff
https://doi.org/10.1200/jco.2011.29.15_suppl.5594

Zobrazit plný text záznamu

Human papillomavirus (HPV)–related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT

Autor: L. Perez-Villa, José M. Jerez, Bella Pajares, Jose Alejandro Medina, M. D. Toledo, A. Rueda, Lissette Pérez, E. Alba, C González-Hermoso, J. M. Trigo Perez, Martina Alvarez, Begoña Jimenez

Publikováno v: Journal of Clinical Oncology. 29:5528-5528

5528 Background: HPV-related HNSCC has been associated with an improved prognosis in patients treated with RT +/- CT; however, no information is available regarding patients treated with RT + EGFR ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd4934e1686ed3ebfb928a6bc7d3fec1
https://doi.org/10.1200/jco.2011.29.15_suppl.5528

Zobrazit plný text záznamu

Association of vascular endothelial growth factor (VEGF) with outcome in metastatic solid tumor treated with antiangiogenic therapy

Autor: Bella Pajares, Mario Perez, J. L. Garcia-Puche, J. M. Jurado-Garcia, Isabel Sevilla, L. Alonso-Carrion, J. M. Trigo Perez, E. Alba

Publikováno v: Journal of Clinical Oncology. 28:e21106-e21106

e21106 Background: Vascular endothelial growth factor (VEGF) have important roles in angiogenesis, predicting risk and prognosis in several solids tumor. VEGF-2578 AA and VEGF-1154 AA genotypes wer...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d158bd19d6e6e637a8aee4c5e862d1aa
https://doi.org/10.1200/jco.2010.28.15_suppl.e21106

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání